News · 26 weeks39+67%
2026-03-012026-08-23
Mix2690d
- SEC Filings10(38%)
- Insider10(38%)
- Other6(23%)
Latest news
25 items- SECSEC Form S-4 filed by NextCure Inc.S-4 - NextCure, Inc. (0001661059) (Filer)
- SECSEC Form SCHEDULE 13G filed by NextCure Inc.SCHEDULE 13G - NextCure, Inc. (0001661059) (Subject)
- INSIDERFormer 10% Owner Simcere Zaiming, Inc. sold $184,800 worth of shares (30,000 units at $6.16) (SEC Form 4)4 - NextCure, Inc. (0001661059) (Issuer)
- SECSEC Form 425 filed by NextCure Inc.425 - NextCure, Inc. (0001661059) (Subject)
- PRAvere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced a $500 million private placement (the "Private Placement") from a syndicate of leading healthcare investors. The Private Placement is in addition to the previously announced $320 million concurre
- SECSEC Form 10-Q filed by NextCure Inc.10-Q - NextCure, Inc. (0001661059) (Filer)
- SECNextCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure Provides Business Update and Reports Second Quarter 2026 Financial ResultsAnnounced Proposed Merger with Avere TherapeuticsPreserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported second quarter 2026 financial results. "Following quarter end, we announced our proposed merger with Avere Therapeutics, together with Avere’s concurrent private financing expected to generate approximately $320 million in gross proceeds, and we are working toward a closing in the second half of
- SECSEC Form 425 filed by NextCure Inc.425 - NextCure, Inc. (0001661059) (Subject)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $1,624,120 worth of shares (329,153 units at $4.93) (SEC Form 4)4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERLarge owner Adar1 Capital Management, Llc bought $87,713 worth of shares (17,608 units at $4.98) (SEC Form 4)4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERNew insider Adar1 Capital Management, Llc claimed ownership of 375,658 shares (SEC Form 3)3 - NextCure, Inc. (0001661059) (Issuer)
- SECSEC Form 425 filed by NextCure Inc.425 - NextCure, Inc. (0001661059) (Subject)
- SECSEC Form 425 filed by NextCure Inc.425 - NextCure, Inc. (0001661059) (Subject)
- SECNextCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal Activities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- PRNextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 TherapyAvere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as a convenient, once-weekly oral therapy Concurrent $320 million private investment from world-class investor syndicate ensures combined company is well-capitalized to accelerate development of AVR-001 Company’s financial runway expected to fund AVR-001 through Phase 2b readout in psoriasis, initiation of a Phase 3 trial in psoriasis, and initiation of a Phase 2b trial in ulcerative colitis Company to be led by a seasoned team of biotech executives: Andrew Cheng, MD, PhD as CEO, President, & C
- SECNextCure Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
- INSIDERSEC Form 4 filed by Director Borgman Anne Elizabeth4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Director Jones Elaine V4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Director Feigal Ellen4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Director Kabakoff David S4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Director Webster Stephen W4 - NextCure, Inc. (0001661059) (Issuer)
- INSIDERSEC Form 4 filed by Director Houston John G4 - NextCure, Inc. (0001661059) (Issuer)
- PRNXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic CancersBELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. The virtual KOL Event is accessible here. The event featured: Beryl Manning-Geist
- SECNextCure Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NextCure, Inc. (0001661059) (Filer)
NXTC FAQ
7 questionsWhat does NextCure Inc. do?
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; and NC762, an immunomedicine targeting a...Where does NXTC stock trade?
NextCure Inc. (NXTC) is listed on NASDAQ.What sector and industry is NXTC in?
NextCure Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NextCure Inc. go public?
NextCure Inc. (NXTC) completed its IPO in 2019.What are analysts saying about NXTC?
NextCure Inc. has had 4 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $1800.00 price target on 2025-11-07. Recent price targets range from $1400.00 to $1800.00.What companies are similar to NXTC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare NXTC side-by-side with any of them on Quantisnow.How can I track NXTC on Quantisnow?
Quantisnow aggregates NextCure Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXTC to receive live email and push alerts on every new disclosure.